Investor
relations
Investor Relations
Company Overview
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance including
Immuno-supression
Exhausted T cells
Poor tumor immunogenicity
Kineta is a leader in developing fully human antibody drugs directed against novel innate immune targets. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies. With KVA12123 in an ongoing Phase 1/2 clinical studying and the lead anti-CD27 agonist mAb in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.
Stock Quote
Company Presentation
Recent Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor
Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.